1. Home
  2. TBPH vs BW Comparison

TBPH vs BW Comparison

Compare TBPH & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$13.86

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Babcock & Wilcox Enterprises Inc.

BW

Babcock & Wilcox Enterprises Inc.

HOLD

Current Price

$14.12

Market Cap

919.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
BW
Founded
2013
1867
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building Products
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
919.9M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
TBPH
BW
Price
$13.86
$14.12
Analyst Decision
Strong Buy
Buy
Analyst Count
5
3
Target Price
$18.50
$7.00
AVG Volume (30 Days)
782.6K
4.7M
Earning Date
05-07-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.88
N/A
Revenue
$15,386,000.00
N/A
Revenue This Year
$70.90
$16.59
Revenue Next Year
N/A
$14.08
P/E Ratio
$15.75
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.90
$0.22
52 Week High
$21.03
$15.29

Technical Indicators

Market Signals
Indicator
TBPH
BW
Relative Strength Index (RSI) 27.74 61.48
Support Level $13.41 $8.03
Resistance Level $14.76 N/A
Average True Range (ATR) 0.58 1.45
MACD -0.08 0.19
Stochastic Oscillator 11.29 84.60

Price Performance

Historical Comparison
TBPH
BW

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

Share on Social Networks: